Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEPPT: Adagrasib in KRASG12C-mutant NSCLC
NCT05673187Phase 2Active, not recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Jun 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of adagrasib in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Objective Response Rate at 12 weeks. Started Jun 2023; status: active, not recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05673187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673187.